Thompson Street Capital Partners Acquires LifeSpan Biosciences (LSBio)
September 17, 2018
Thompson Street Capital Partners (TSCP), a St. Louis-based private equity firm, has partnered with management to acquire Seattle-based LifeSpan Biosciences, Inc. (LSBio), a developer and e‑commerce distributor of antibodies, kits, proteins and related reagents for academic and pharmaceutical research. TSCP said it will support LSBio's strategy to expand its catalog and capabilities organically and via targeted acquisitions; terms were not disclosed.
- Targets
- LifeSpan Biosciences, Inc. (LSBio)
- Industry
- Biotechnology
- Location
- Washington, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
Keensight Capital Acquires Majority Stake in Isto Biologics
September 22, 2025
Healthcare Services
Keensight Capital has agreed to acquire a majority stake in regenerative MedTech company Isto Biologics. Thompson Street Capital Partners (TSCP) will retain a minority stake alongside Isto’s management team.
-
Thompson Street Capital Partners Makes Growth Investment in OpenClinica
February 21, 2023
Healthcare Services
Thompson Street Capital Partners (TSCP) has completed a growth investment in OpenClinica, a Waltham, Massachusetts–based cloud-first eClinical platform that automates clinical data capture and integrates with EHRs. The investment will support OpenClinica’s expansion of its Unite EHR-connected network and the company’s broader product and market growth; terms were not disclosed.
-
Thompson Street Capital Partners Makes Growth Investment in Sabai Global
February 6, 2023
Healthcare Services
Thompson Street Capital Partners (TSCP) completed a growth investment in Sabai Global, a Chesterfield, Missouri-based provider of biosafety consulting, regulatory review, and central IRB services for clinical research. The investment will support Sabai’s continued expansion of services—particularly in cell and gene therapy—across pharmaceutical sponsors, CROs, academic health systems, and clinical research site networks.
-
Isto Biologics (TSCP Portfolio) Acquires TheraCell
April 5, 2022
Medical Devices
Isto Biologics, a portfolio company of Thompson Street Capital Partners, has acquired TheraCell, a Los Angeles–based regenerative medicine company known for its TheraFuze DBF bone-fiber technology. The deal expands Isto's orthobiologics product portfolio—adding TheraCell's proprietary spinal repair technologies to Isto's Influx line—and aims to accelerate surgical adoption through Isto's commercial and clinical teams. Terms were not disclosed.
-
EQT Acquires LSP (Life Sciences Partners)
November 10, 2021
Financial Services
EQT AB has acquired LSP (Life Sciences Partners), a leading European life-sciences venture capital firm, in a transaction that creates a new EQT Life Sciences business line. The deal values the upfront consideration at EUR 450 million (25% cash / 75% EQT shares) with a EUR 25 million earn‑out paid on meeting fundraising targets (total consideration EUR 475 million at close); LSP's 34-person team and partners join EQT to strengthen its healthcare investing capabilities.
-
Public Pension Capital Invests in Life Science Outsourcing, Inc.
January 25, 2021
Medical Devices
Public Pension Capital, a New York-based private equity fund, made an investment in Life Science Outsourcing, Inc., a Brea, California-based contract manufacturer serving medical device companies. The transaction, completed January 25, 2021, will support LSO's medical package testing, validation, sterilization and distribution services and help accelerate the company's growth and capacity to serve device startups and larger OEMs.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.